Regeneron Pharmaceuticals announced that its Phase 3 melanoma trial combining fianlimab and Libtayo did not meet the primary endpoint against Keytruda, causing the stock to fall more than 10%. Prior optimism from company executives about the trial's progress led to significant investor losses. Legal firm Levi & Korsinsky is investigating whether Regeneron made misleading statements about the trial's potential and is encouraging affected investors to review their rights and consider participating in a securities investigation. No immediate action is required to remain eligible for potential recovery claims.
Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial involving fianlimab and Libtayo. In March 2026, Regeneron's investor relations VP expressed optimi...
The Nasdaq Composite fell 0.68% due to rising 10-year U.S. Treasury yields hitting 4.63%, the highest since February 2025, which increased borrowing costs and made bonds more attractive than stocks. This shift particularly impacted AI-driven tech and...
Regeneron Pharmaceuticals faced a setback as its drugs fianlimab and Libtayo failed to meet endpoints in a phase 3 trial for first-line metastatic melanoma, causing shares to drop. However, this failure is not seen as critical for Regeneron's long-te...
Regeneron Pharmaceuticals' stock fell over 10% following the Phase 3 trial results for their melanoma treatment combining fianlimab and cemiplimab. The trial did not achieve statistical significance for the primary endpoint of progression-free surviv...
Regeneron Pharmaceuticals' phase 3 trial for its melanoma drug fianlimab, combined with cemiplimab, failed to meet the primary goal of significantly improving progression-free survival compared to Merck's Keytruda. Although the combination extended m...
